{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966263",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966263_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  St John's wort  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966264",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966264_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"abrocitinib\" outputclass=\"int-drug\">abrocitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"abrocitinib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/abrocitinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP223393\">abrocitinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   abrocitinib .  Manufacturer advises adjust  abrocitinib  dose .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Abrocitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966265",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966265_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"acalabrutinib\" outputclass=\"int-drug\">acalabrutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  acalabrutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acalabrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966266",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966266_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  aceclofenac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966266_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  aceclofenac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966267",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966267_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">Acenocoumarol</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acenocoumarol   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966268",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966268_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"agomelatine\" outputclass=\"int-drug\">agomelatine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   very markedly   increases   the exposure to   agomelatine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Agomelatine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966269",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966269_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"almotriptan\" outputclass=\"int-drug\">almotriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  almotriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Almotriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966270",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966270_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"alprazolam\" outputclass=\"int-drug\">alprazolam</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   moderately   increases   the exposure to   alprazolam .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966271",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966271_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"alprostadil\" outputclass=\"int-drug\">alprostadil</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  alprostadil  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprostadil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966272",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966272_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alteplase\" outputclass=\"int-drug\">Alteplase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alteplase   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966273",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966273_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  amiloride  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966274",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966274_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">moderately to markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"aminophylline\" outputclass=\"int-drug\">aminophylline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   moderately to markedly   increases   the exposure to   aminophylline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aminophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966275",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966275_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  amitriptyline  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966275_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Fluvoxamine   increases   the exposure to   amitriptyline .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966276",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966276_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  anagrelide  can increase the risk of bleeding.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966276_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   anagrelide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966277",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966277_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apixaban\" outputclass=\"int-drug\">Apixaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apixaban   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966278",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966278_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"argatroban\" outputclass=\"int-drug\">Argatroban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Argatroban   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Argatroban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966279",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966279_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"asenapine\" outputclass=\"int-drug\">asenapine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   increases   the exposure to   asenapine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asenapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966280",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966280_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  aspirin  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966281",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966281_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  axitinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966282",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966282_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bemiparin\" outputclass=\"int-drug\">Bemiparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bemiparin   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bemiparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966283",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966283_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  bendroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966284",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966284_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"benzydamine\" outputclass=\"int-drug\">benzydamine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  benzydamine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benzydamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966285",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966285_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   causes   bleeding, as can   bevacizumab   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966286",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966286_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bivalirudin\" outputclass=\"int-drug\">Bivalirudin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bivalirudin   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bivalirudin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966287",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966287_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  bosutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966288",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966288_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"bromfenac\" outputclass=\"int-drug\">bromfenac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  bromfenac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromfenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966289",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966289_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  bumetanide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966290",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966290_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bupropion\" outputclass=\"int-drug\">Bupropion</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">enhance</ph> <ph outputclass=\"int-parameter\">the risk of serotonin syndrome when given with</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph>. <ph outputclass=\"int-action\">MHRA advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bupropion   might   enhance   the risk of serotonin syndrome when given with   fluvoxamine .  MHRA advises monitor .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupropion</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966291",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966291_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   causes   bleeding, as can   cabozantinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966292",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966292_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the clearance of</ph> <ph otherprops=\"caffeine citrate\" outputclass=\"int-drug\">caffeine citrate</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   markedly   decreases   the clearance of   caffeine citrate .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Caffeine citrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966293",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966293_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"cangrelor\" outputclass=\"int-drug\">cangrelor</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  cangrelor  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cangrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966294",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966294_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cannabidiol\" outputclass=\"int-drug\">cannabidiol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   cannabidiol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cannabidiol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966295",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966295_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"caplacizumab\" outputclass=\"int-drug\">caplacizumab</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   causes   bleeding, as can   caplacizumab   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Caplacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966296",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966296_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">carbamazepine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  carbamazepine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966297",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966297_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  celecoxib  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966297_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  celecoxib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966298",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966298_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  chlorothiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966299",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966299_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   chlorpromazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorpromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966300",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966300_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  chlortalidone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966301",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966301_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">cilostazol</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  cilostazol  can increase the risk of bleeding.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966301_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">cilostazol</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"cilostazol\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/cilostazol.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1396\">cilostazol</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   cilostazol .  Manufacturer advises adjust  cilostazol  dose .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cilostazol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966302",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966302_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cinacalcet\" outputclass=\"int-drug\">cinacalcet</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   cinacalcet .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cinacalcet</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966303",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966303_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   citalopram .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966304",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966304_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clobazam\" outputclass=\"int-drug\">clobazam</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   potentially   increases   the exposure to   clobazam .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clobazam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966305",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966305_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  clomipramine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966305_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  clomipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966305_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Fluvoxamine   markedly   increases   the exposure to   clomipramine .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966306",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966306_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">clopidogrel</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  clopidogrel  can increase the risk of bleeding.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966306_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">clopidogrel</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Fluvoxamine   is predicted to   decrease   the efficacy of   clopidogrel .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966307",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966307_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   increases   the concentration of   clozapine .  Manufacturer advises monitor adverse effects and adjust dose .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clozapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966308",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966308_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cobimetinib\" outputclass=\"int-drug\">cobimetinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   causes   bleeding, as can   cobimetinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobimetinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966309",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966309_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cyproheptadine\" outputclass=\"int-drug\">Cyproheptadine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cyproheptadine   potentially   decreases   the effects of   fluvoxamine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyproheptadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966310",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966310_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">Dabigatran</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabigatran   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966311",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966311_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">Dalteparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dalteparin   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966312",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966312_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"danaparoid\" outputclass=\"int-drug\">Danaparoid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Danaparoid   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Danaparoid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966313",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966313_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  dasatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966314",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966314_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"desmopressin\" outputclass=\"int-drug\">desmopressin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  desmopressin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desmopressin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966315",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966315_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"dexamfetamine\" outputclass=\"int-drug\">dexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  dexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966316",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966316_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  dexketoprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966316_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  dexketoprofen  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966317",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966317_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"diazepam\" outputclass=\"int-drug\">diazepam</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   moderately   increases   the exposure to   diazepam .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966318",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966318_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  diclofenac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966318_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  diclofenac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966319",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966319_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  dipyridamole  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966320",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966320_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  dosulepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966321",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966321_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  doxepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966322",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966322_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   fluvoxamine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966323",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966323_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  duloxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966323_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  duloxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966323_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Both  fluvoxamine  and  duloxetine  can increase the risk of bleeding.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966323_message_3",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "4",
							"hasTextContent": "Fluvoxamine   markedly   increases   the exposure to   duloxetine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966324",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966324_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">Edoxaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Edoxaban   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966325",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966325_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"eicosapentaenoic acid\" outputclass=\"int-drug\">eicosapentaenoic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  eicosapentaenoic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eicosapentaenoic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966326",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966326_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"eletriptan\" outputclass=\"int-drug\">eletriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  eletriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eletriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966327",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966327_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"eltrombopag\" outputclass=\"int-drug\">eltrombopag</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   eltrombopag .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eltrombopag</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966328",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966328_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">Enoxaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enoxaparin   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966329",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966329_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  eplerenone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966330",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966330_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  epoprostenol  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966331",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966331_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eptifibatide\" outputclass=\"int-drug\">Eptifibatide</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eptifibatide   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eptifibatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966332",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966332_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">erlotinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor adverse effects and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   erlotinib .  Manufacturer advises monitor adverse effects and adjust dose .    \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966333",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966333_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   escitalopram .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966334",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966334_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  etodolac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966334_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  etodolac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966335",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966335_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  etoricoxib  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966335_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  etoricoxib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966336",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966336_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fedratinib\" outputclass=\"int-drug\">fedratinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   fedratinib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fedratinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966337",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966337_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"fenfluramine\" outputclass=\"int-drug\">fenfluramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  fenfluramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenfluramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966338",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966338_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  fentanyl  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966339",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966339_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  flurbiprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966339_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  flurbiprofen  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966340",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966340_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fondaparinux\" outputclass=\"int-drug\">Fondaparinux</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fondaparinux   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fondaparinux</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966341",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966341_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">fosphenytoin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the concentration of   fosphenytoin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966342",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966342_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"frovatriptan\" outputclass=\"int-drug\">frovatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  frovatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966342_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"frovatriptan\" outputclass=\"int-drug\">frovatriptan</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Fluvoxamine   increases   the concentration of   frovatriptan .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Frovatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966343",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966343_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  furosemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966344",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966344_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  gabapentin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966345",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966345_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"granisetron\" outputclass=\"int-drug\">granisetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  granisetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966346",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966346_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   increases   the concentration of   haloperidol .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Haloperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966347",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966347_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"heparin\" outputclass=\"int-drug\">Heparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Heparin   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966348",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966348_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  hydrochlorothiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966349",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966349_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  hydroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966350",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966350_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  ibrutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966351",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966351_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  ibuprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966351_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  ibuprofen  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966352",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966352_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  iloprost  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966353",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966353_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  imatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966354",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966354_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  imipramine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966354_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  imipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966354_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Fluvoxamine   increases   the exposure to   imipramine .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966355",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966355_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  indapamide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966356",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966356_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  indometacin  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966356_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  indometacin  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966357",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966357_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   causes   bleeding, as can   inotersen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotersen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966358",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966358_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  isocarboxazid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966359",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966359_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  ketoprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966359_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  ketoprofen  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966360",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966360_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  ketorolac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966360_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  ketorolac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966361",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966361_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  lenvatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966362",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966362_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  linezolid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linezolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966363",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966363_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"lisdexamfetamine\" outputclass=\"int-drug\">lisdexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  lisdexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisdexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966364",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966364_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  lithium  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966365",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966365_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lomitapide\" outputclass=\"int-drug\">lomitapide</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 12 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   lomitapide .  Manufacturer advises separate administration by 12 hours .    \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomitapide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966366",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966366_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Unknown\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"loxapine\" outputclass=\"int-drug\">loxapine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Unknown",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   loxapine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loxapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966367",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966367_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  mefenamic acid  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966367_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  mefenamic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966368",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966368_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"melatonin\" outputclass=\"int-drug\">melatonin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   very markedly   increases   the exposure to   melatonin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Melatonin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966369",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966369_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  meloxicam  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966369_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  meloxicam  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966370",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966370_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  methadone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966371",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966371_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"methylthioninium chloride\" outputclass=\"int-drug\">methylthioninium chloride</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  methylthioninium chloride  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylthioninium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966372",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966372_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  metolazone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966373",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966373_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"mexiletine\" outputclass=\"int-drug\">mexiletine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor ECG</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   mexiletine .  Manufacturer advises monitor ECG .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mexiletine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966374",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966374_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  mirtazapine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirtazapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966375",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966375_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Unknown\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of prolonged neuromuscular blockade when given with</ph> <ph otherprops=\"mivacurium\" outputclass=\"int-drug\">mivacurium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Unknown",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   potentially   increases   the risk of prolonged neuromuscular blockade when given with   mivacurium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mivacurium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966376",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966376_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"moclobemide\" outputclass=\"int-drug\">moclobemide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  moclobemide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moclobemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966377",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966377_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  nabumetone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966377_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  nabumetone  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966378",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966378_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  naproxen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966378_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  naproxen  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966379",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966379_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"naratriptan\" outputclass=\"int-drug\">naratriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  naratriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naratriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966380",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966380_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">Nicotinic acid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicotinic acid   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966381",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966381_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"nintedanib\" outputclass=\"int-drug\">nintedanib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  nintedanib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nintedanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966382",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966382_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  nortriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966383",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966383_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   moderately   increases   the exposure to   olanzapine .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olanzapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966384",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966384_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"omega-3-acid ethyl esters\" outputclass=\"int-drug\">omega-3-acid ethyl esters</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  omega-3-acid ethyl esters  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omega-3-acid ethyl esters</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966385",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966385_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  ondansetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966386",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966386_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of adverse effects when given with</ph> <ph otherprops=\"ozanimod\" outputclass=\"int-drug\">ozanimod</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   might   increase   the risk of adverse effects when given with   ozanimod .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ozanimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966387",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966387_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">palonosetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  palonosetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966388",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966388_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  parecoxib  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966388_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  parecoxib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966389",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966389_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  pazopanib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966390",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966390_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  pentazocine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentazocine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966391",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966391_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pentoxifylline\" outputclass=\"int-drug\">pentoxifylline</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   pentoxifylline .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentoxifylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966392",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966392_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  pethidine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966393",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966393_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"phenazone\" outputclass=\"int-drug\">phenazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  phenazone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966393_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"phenazone\" outputclass=\"int-drug\">phenazone</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  phenazone  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966394",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966394_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  phenelzine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966395",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966395_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenindione\" outputclass=\"int-drug\">Phenindione</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenindione   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966396",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966396_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">phenytoin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the concentration of   phenytoin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966397",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966397_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pirfenidone\" outputclass=\"int-drug\">pirfenidone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   moderately   increase   the exposure to   pirfenidone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pirfenidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966398",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966398_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  piroxicam  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966398_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  piroxicam  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966399",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966399_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pomalidomide\" outputclass=\"int-drug\">pomalidomide</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"pomalidomide\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/pomalidomide.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34116\">pomalidomide</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   moderately   increases   the exposure to   pomalidomide .  Manufacturer advises adjust  pomalidomide  dose .    \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pomalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966400",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966400_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"ponatinib\" outputclass=\"int-drug\">ponatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  ponatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ponatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966401",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966401_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"prasugrel\" outputclass=\"int-drug\">prasugrel</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  prasugrel  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prasugrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966402",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966402_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"propafenone\" outputclass=\"int-drug\">propafenone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   propafenone .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propafenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966403",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966403_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"propranolol\" outputclass=\"int-drug\">propranolol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   moderately   increases   the concentration of   propranolol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propranolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966404",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966404_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">rasagiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  rasagiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rasagiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966405",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966405_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  regorafenib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966406",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966406_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"riluzole\" outputclass=\"int-drug\">riluzole</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   riluzole .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Riluzole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966407",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966407_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">Rivaroxaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rivaroxaban   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966408",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966408_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"rizatriptan\" outputclass=\"int-drug\">rizatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  rizatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rizatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966409",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966409_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"roflumilast\" outputclass=\"int-drug\">roflumilast</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   roflumilast .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Roflumilast</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966410",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966410_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ropinirole\" outputclass=\"int-drug\">ropinirole</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   ropinirole .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropinirole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966411",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966411_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the clearance of</ph> <ph otherprops=\"ropivacaine\" outputclass=\"int-drug\">ropivacaine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid prolonged use</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   decreases   the clearance of   ropivacaine .  Manufacturer advises avoid prolonged use .    \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966412",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966412_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966413",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966413_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"safinamide\" outputclass=\"int-drug\">safinamide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  safinamide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Safinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966414",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966414_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  selegiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966415",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966415_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"selumetinib\" outputclass=\"int-drug\">selumetinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor—consult product literature</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   selumetinib .  Manufacturer advises avoid or monitor—consult product literature .    \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selumetinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966416",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966416_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"sodium picosulfate\" outputclass=\"int-drug\">sodium picosulfate</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  sodium picosulfate  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium picosulfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966417",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966417_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  sorafenib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966418",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966418_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  spironolactone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966419",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966419_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"streptokinase\" outputclass=\"int-drug\">Streptokinase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Streptokinase   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966420",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966420_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  sulindac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966420_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  sulindac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966421",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966421_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"sumatriptan\" outputclass=\"int-drug\">sumatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  sumatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sumatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966422",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966422_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  sunitinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966423",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966423_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Unknown\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of prolonged neuromuscular blockade when given with</ph> <ph otherprops=\"suxamethonium\" outputclass=\"int-drug\">suxamethonium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Unknown",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   potentially   increases   the risk of prolonged neuromuscular blockade when given with   suxamethonium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Suxamethonium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966424",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966424_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">very slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"talazoparib\" outputclass=\"int-drug\">talazoparib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   very slightly   increases   the exposure to   talazoparib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Talazoparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966425",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966425_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">Tapentadol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of serotonin syndrome when given with</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tapentadol   is predicted to   increase   the risk of serotonin syndrome when given with   fluvoxamine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tapentadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966426",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966426_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenecteplase\" outputclass=\"int-drug\">Tenecteplase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenecteplase   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenecteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966427",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966427_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  tenoxicam  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966427_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  tenoxicam  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966428",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966428_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"terbinafine\" outputclass=\"int-drug\">Terbinafine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Terbinafine   is predicted to   increase   the exposure to   fluvoxamine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbinafine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966429",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966429_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">moderately to markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"theophylline\" outputclass=\"int-drug\">theophylline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   moderately to markedly   increases   the exposure to   theophylline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Theophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966430",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966430_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  tiaprofenic acid  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966430_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  tiaprofenic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966431",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966431_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"ticagrelor\" outputclass=\"int-drug\">ticagrelor</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  ticagrelor  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ticagrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966432",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966432_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966433",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966433_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tirofiban\" outputclass=\"int-drug\">Tirofiban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tirofiban   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tirofiban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966434",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966434_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   very markedly   increases   the exposure to   tizanidine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tizanidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966435",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966435_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">given with a moderate CYP3A4 inhibitor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tofacitinib\" outputclass=\"int-drug\">tofacitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"tofacitinib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/tofacitinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP213798\">tofacitinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   given with a moderate CYP3A4 inhibitor   is predicted to   increase   the exposure to   tofacitinib .  Manufacturer advises adjust  tofacitinib  dose .    \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tofacitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966436",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966436_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  tolfenamic acid  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966436_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  tolfenamic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966437",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966437_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  torasemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966438",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966438_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  tramadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tramadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966439",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966439_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"trametinib\" outputclass=\"int-drug\">trametinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   causes   bleeding, as can   trametinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trametinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966440",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966440_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  tranylcypromine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966441",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966441_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   causes   bleeding, as can   trastuzumab emtansine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966442",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966442_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  trazodone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966443",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966443_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"treprostinil\" outputclass=\"int-drug\">treprostinil</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  treprostinil  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treprostinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  triamterene  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  trimethoprim  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  trimipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"tryptophan\" outputclass=\"int-drug\">tryptophan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  tryptophan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tryptophan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"urokinase\" outputclass=\"int-drug\">Urokinase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Urokinase   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Urokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966449",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966449_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  venlafaxine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966449_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  venlafaxine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"volanesorsen\" outputclass=\"int-drug\">volanesorsen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid depending on platelet count—consult product literature</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fluvoxamine   causes   bleeding, as can   volanesorsen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises avoid depending on platelet count—consult product literature .    \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Volanesorsen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  vortioxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966451_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  fluvoxamine  and  vortioxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"warfarin\" outputclass=\"int-drug\">Warfarin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Warfarin   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  xipamide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">fluvoxamine</ph> and <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\">zolmitriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  fluvoxamine  and  zolmitriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine#bnf_i1643857966454_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-heading-drug\">Fluvoxamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\">zolmitriptan</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/zolmitriptan.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP2859\">zolmitriptan</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Fluvoxamine   is predicted to   increase   the exposure to   zolmitriptan .  Manufacturer advises adjust  zolmitriptan  dose .    \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolmitriptan</title>"
					}
				}
			],
			"hasSearchLabel": " Fluvoxamine  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/fluvoxamine.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Fluvoxamine </title>"
			},
			"rdfs:label": "fluvoxamine"
		}
	]
}